Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals, a biopharmaceutical company focused on the research, development and commercialisation of pharmaceutical products, has reported a revenue of $168.5m for the second quarter ended June 30, 2010, an increase of 29%, compared to $130.8m in the second quarter of 2009.
Subscribe to our email newsletter
Cubist Pharma said that the increase was attributable primarily to its net sales of Cubicin (daptomycin for injection) in the US, which increased 23% to $155m from $126.1m during the same period in 2009.
Cubist Pharma has posted a net income of $28.1m compared to $23.8m for the comparable period in 2009. Operating income was $53.7m, compared to $35.9m for the comparable period in 2009.
Additionally, for the six months ended June 30, 2010, Cubist Pharma has posted a net income of $48.5m, or $0.80 per diluted share, compared to $31.5m, or $0.54 per diluted share, for the year ago period. Revenue was $312.6m compared to $2518m for the year ago period. Operating income was $91m, compared to $51.6m for the year ago period.